SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'PBZ'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1AQ7_B_AG2B4_1 (TRYPSIN AERUGINOSIN 98-B)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	6 / 8	HIS A 57 ASP A 189 GLN A 192 SER A 195 GLY A 216 GLY A 226	None PBZ A 305 (-2.7A) PBZ A 305 (-3.2A) PBZ A 305 (-2.9A) PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.90A	1aq7A-1fiwA: 34.4	1aq7A-1fiwA: 34.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1AQ7_B_AG2B4_1 (TRYPSIN AERUGINOSIN 98-B)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	6 / 8	HIS A 57 ASP A 189 GLN A 192 SER A 195 GLY A 216 GLY A 226	None PBZ A 308 (-2.9A) PBZ A 308 (-3.6A) PBZ A 308 (-3.2A) PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A)	0.68A	1aq7A-1fizA: 33.8	1aq7A-1fizA: 37.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1BCU_H_PRLH280_0 (ALPHA-THROMBIN)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	5 / 9	ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) None PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.38A	1bcuH-1fiwA: 35.4	1bcuH-1fiwA: 31.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1BCU_H_PRLH280_0 (ALPHA-THROMBIN)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	5 / 9	ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	PBZ A 308 (-2.9A) PBZ A 308 (-3.2A) None PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A)	0.52A	1bcuH-1fizA: 17.5	1bcuH-1fizA: 35.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1DWC_H_MITH1_1 (ALPHA-THROMBIN (LARGE SUBUNIT))	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	5 / 9	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 226	None PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) None PBZ A 305 (-3.3A)	0.47A	1dwcH-1fiwA: 34.8	1dwcH-1fiwA: 31.51
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1DWC_H_MITH1_1 (ALPHA-THROMBIN (LARGE SUBUNIT))	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	5 / 9	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 226	None PBZ A 308 (-2.9A) PBZ A 308 (-3.2A) None PBZ A 308 ( 3.7A)	0.41A	1dwcH-1fizA: 34.3	1dwcH-1fizA: 35.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1ETR_H_MITH1_1 (EPSILON-THROMBIN)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	6 / 12	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	None PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) None PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.60A	1etrH-1fiwA: 34.7	1etrH-1fiwA: 34.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1ETR_H_MITH1_1 (EPSILON-THROMBIN)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	6 / 12	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	None PBZ A 308 (-2.9A) PBZ A 308 (-3.2A) None PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A)	0.54A	1etrH-1fizA: 34.1	1etrH-1fizA: 35.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1F5L_A_AMRA301_1 (UROKINASE-TYPE PLASMINOGEN ACTIVATOR)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	4 / 8	ASP A 189 SER A 195 GLY A 216 GLY A 226	PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.30A	1f5lA-1fiwA: 36.6	1f5lA-1fiwA: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1F5L_A_AMRA301_1 (UROKINASE-TYPE PLASMINOGEN ACTIVATOR)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	4 / 8	ASP A 189 SER A 195 GLY A 216 GLY A 226	PBZ A 308 (-2.9A) PBZ A 308 (-3.2A) PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A)	0.43A	1f5lA-1fizA: 36.3	1f5lA-1fizA: 32.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TNL_A_TPAA900_1 (TRYPSIN)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	4 / 6	ASP A 189 SER A 195 GLY A 216 GLY A 226	PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.35A	1tnlA-1fiwA: 16.2	1tnlA-1fiwA: 34.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1TNL_A_TPAA900_1 (TRYPSIN)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	4 / 6	ASP A 189 SER A 195 GLY A 216 GLY A 226	PBZ A 308 (-2.9A) PBZ A 308 (-3.2A) PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A)	0.32A	1tnlA-1fizA: 17.0	1tnlA-1fizA: 37.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1X7P_B_SAMB302_0 (RRNA METHYLTRANSFERASE)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	5 / 10	THR A 190 GLY A 140 GLY A 142 ILE A 188 ALA A 158	PBZ A 305 (-3.9A) None None None None	1.10A	1x7pA-1fiwA: undetectable 1x7pB-1fiwA: undetectable	1x7pA-1fiwA: 23.03 1x7pB-1fiwA: 23.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1X7P_B_SAMB302_0 (RRNA METHYLTRANSFERASE)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	5 / 10	THR A 190 GLY A 140 GLY A 142 ILE A 188 ALA A 158	PBZ A 308 (-3.4A) None None None None	1.02A	1x7pA-1fizA: undetectable 1x7pB-1fizA: undetectable	1x7pA-1fizA: 19.47 1x7pB-1fizA: 19.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2OTV_A_NCAA1301_0 (CATIONIC TRYPSIN)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	4 / 6	ASP A 189 SER A 195 GLY A 216 GLY A 226	PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.23A	2otvA-1fiwA: 16.4	2otvA-1fiwA: 34.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2OTV_A_NCAA1301_0 (CATIONIC TRYPSIN)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	4 / 6	ASP A 189 SER A 195 GLY A 216 GLY A 226	PBZ A 308 (-2.9A) PBZ A 308 (-3.2A) PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A)	0.36A	2otvA-1fizA: 17.1	2otvA-1fizA: 37.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2P16_A_GG2A298_1 (COAGULATION FACTOR X (EC 3.4.21.6) (STUART FACTOR) (STUART-PROWER FACTOR))	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	6 / 12	ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226 TYR A 228	PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) None PBZ A 305 (-3.4A) PBZ A 305 (-3.3A) None	0.30A	2p16A-1fiwA: 35.3	2p16A-1fiwA: 31.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2P16_A_GG2A298_1 (COAGULATION FACTOR X (EC 3.4.21.6) (STUART FACTOR) (STUART-PROWER FACTOR))	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	6 / 12	ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226 TYR A 228	PBZ A 308 (-2.9A) PBZ A 308 (-3.2A) None PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A) None	0.41A	2p16A-1fizA: 34.1	2p16A-1fizA: 34.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2VIN_A_505A1247_1 (UROKINASE-TYPE PLASMINOGEN ACTIVATOR CHAIN B)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	4 / 8	ASP A 189 SER A 195 GLY A 216 GLY A 226	PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.34A	2vinA-1fiwA: 37.1	2vinA-1fiwA: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2VIN_A_505A1247_1 (UROKINASE-TYPE PLASMINOGEN ACTIVATOR CHAIN B)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	4 / 8	ASP A 189 SER A 195 GLY A 216 GLY A 226	PBZ A 308 (-2.9A) PBZ A 308 (-3.2A) PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A)	0.33A	2vinA-1fizA: 14.1	2vinA-1fizA: 32.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2W26_A_RIVA1001_1 (ACTIVATED FACTOR XA HEAVY CHAIN)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	7 / 12	ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 219 GLY A 226 TYR A 228	PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) None PBZ A 305 (-3.4A) PBZ A 305 (-4.9A) PBZ A 305 (-3.3A) None	0.34A	2w26A-1fiwA: 35.4	2w26A-1fiwA: 31.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2W26_A_RIVA1001_1 (ACTIVATED FACTOR XA HEAVY CHAIN)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	7 / 12	ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 219 GLY A 226 TYR A 228	PBZ A 308 (-2.9A) PBZ A 308 (-3.2A) None PBZ A 308 (-3.6A) None PBZ A 308 ( 3.7A) None	0.50A	2w26A-1fizA: 16.2	2w26A-1fizA: 34.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3DCM_X_SAMX5452_0 (UNCHARACTERIZED PROTEIN TM_1570)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	5 / 11	THR A 190 GLY A 140 GLY A 142 ILE A 188 ALA A 158	PBZ A 308 (-3.4A) None None None None	0.97A	3dcmX-1fizA: undetectable	3dcmX-1fizA: 21.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GY3_A_PNTA246_0 (CATIONIC TRYPSIN)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	6 / 11	ASP A 189 GLN A 192 SER A 195 TRP A 215 GLY A 216 GLY A 226	PBZ A 305 (-2.7A) PBZ A 305 (-3.2A) PBZ A 305 (-2.9A) None PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.81A	3gy3A-1fiwA: 16.4	3gy3A-1fiwA: 34.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GY3_A_PNTA246_0 (CATIONIC TRYPSIN)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	6 / 11	HIS A 57 ASP A 189 SER A 195 TRP A 215 GLY A 216 GLY A 226	None PBZ A 305 (-2.7A) PBZ A 305 (-2.9A) None PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.37A	3gy3A-1fiwA: 16.4	3gy3A-1fiwA: 34.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GY3_A_PNTA246_0 (CATIONIC TRYPSIN)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	7 / 11	HIS A 57 ASP A 189 GLN A 192 SER A 195 TRP A 215 GLY A 216 GLY A 226	None PBZ A 308 (-2.9A) PBZ A 308 (-3.6A) PBZ A 308 (-3.2A) None PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A)	0.56A	3gy3A-1fizA: 16.9	3gy3A-1fizA: 37.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3RXF_A_4APA9_1 (CATIONIC TRYPSIN)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	4 / 6	SER A 195 TRP A 215 GLY A 216 GLY A 226	PBZ A 305 (-2.9A) None PBZ A 305 (-3.4A) PBZ A 305 (-3.3A)	0.28A	3rxfA-1fiwA: 16.9	3rxfA-1fiwA: 34.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3RXF_A_4APA9_1 (CATIONIC TRYPSIN)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	4 / 6	SER A 195 TRP A 215 GLY A 216 GLY A 226	PBZ A 308 (-3.2A) None PBZ A 308 (-3.6A) PBZ A 308 ( 3.7A)	0.28A	3rxfA-1fizA: 16.5	3rxfA-1fizA: 37.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4FU8_A_ACTA302_0 (UROKINASE-TYPE PLASMINOGEN ACTIVATOR)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	4 / 5	HIS A 57 GLN A 192 GLY A 193 SER A 195	None PBZ A 308 (-3.6A) None PBZ A 308 (-3.2A)	0.87A	4fu8A-1fizA: 36.4	4fu8A-1fizA: 32.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4LRH_B_FOLB301_1 (FOLATE RECEPTOR ALPHA)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	3 / 3	ASP A 102 TRP A 63 SER A 195	None None PBZ A 305 (-2.9A)	1.06A	4lrhB-1fiwA: undetectable	4lrhB-1fiwA: 23.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4LRH_B_FOLB301_1 (FOLATE RECEPTOR ALPHA)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	3 / 3	ASP A 102 TRP A 63 SER A 195	None None PBZ A 308 (-3.2A)	1.07A	4lrhB-1fizA: undetectable	4lrhB-1fizA: 23.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4RDX_A_HISA502_0 (HISTIDINE--TRNA LIGASE)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	4 / 7	THR A 190 GLY A 216 TYR A 228 GLY A 226	PBZ A 308 (-3.4A) PBZ A 308 (-3.6A) None PBZ A 308 ( 3.7A)	0.91A	4rdxA-1fizA: undetectable	4rdxA-1fizA: 20.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6C2M_C_SUEC1203_0 (NS3 PROTEASE)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	5 / 12	HIS A 57 ASP A 102 GLY A 193 SER A 195 VAL A 217	None None None PBZ A 305 (-2.9A) None	0.95A	6c2mC-1fiwA: 9.7	6c2mC-1fiwA: 16.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6C2M_C_SUEC1203_0 (NS3 PROTEASE)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	5 / 12	HIS A 57 ASP A 102 GLY A 193 SER A 195 VAL A 217	None None None PBZ A 308 (-3.2A) None	0.88A	6c2mC-1fizA: 9.5	6c2mC-1fizA: 16.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HU9_H_PCFH604_0 (CYTOCHROME B-C1 COMPLEX SUBUNIT 8 CYTOCHROME C OXIDASE POLYPEPTIDE 5A, MITOCHONDRIAL)	1fiw	BETA-ACROSIN HEAVY CHAIN (Ovis aries)	4 / 8	GLY A 216 GLY A 193 SER A 195 ALA A 55	PBZ A 305 (-3.4A) None PBZ A 305 (-2.9A) None	0.76A	6hu9H-1fiwA: undetectable 6hu9e-1fiwA: undetectable	6hu9H-1fiwA: 14.79 6hu9e-1fiwA: 18.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HU9_H_PCFH604_0 (CYTOCHROME B-C1 COMPLEX SUBUNIT 8 CYTOCHROME C OXIDASE POLYPEPTIDE 5A, MITOCHONDRIAL)	1fiz	BETA-ACROSIN HEAVY CHAIN (Sus scrofa)	4 / 8	GLY A 216 GLY A 193 SER A 195 ALA A 55	PBZ A 308 (-3.6A) None PBZ A 308 (-3.2A) None	0.78A	6hu9H-1fizA: undetectable 6hu9e-1fizA: undetectable	6hu9H-1fizA: 12.98 6hu9e-1fizA: 19.77

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1AQ7_B_AG2B4_1","TRYPSIN;AERUGINOSIN 98-B","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",6,"HIS A  57;ASP A 189;GLN A 192;SER A 195;GLY A 216;GLY A 226","None;PBZ A 305 (-2.7A);PBZ A 305 (-3.2A);PBZ A 305 (-2.9A);PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.90A","1aq7A-1fiwA:34.4",null],["1AQ7_B_AG2B4_1","TRYPSIN;AERUGINOSIN 98-B","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",6,"HIS A  57;ASP A 189;GLN A 192;SER A 195;GLY A 216;GLY A 226","None;PBZ A 308 (-2.9A);PBZ A 308 (-3.6A);PBZ A 308 (-3.2A);PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A)","0.68A","1aq7A-1fizA:33.8","1aq7A-1fiwA:34.60"],["1BCU_H_PRLH280_0","ALPHA-THROMBIN","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",5,"ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);None;PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.38A","1bcuH-1fiwA:35.4","1aq7A-1fizA:37.70"],["1BCU_H_PRLH280_0","ALPHA-THROMBIN","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",5,"ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","PBZ A 308 (-2.9A);PBZ A 308 (-3.2A);None;PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A)","0.52A","1bcuH-1fizA:17.5","1bcuH-1fiwA:31.51"],["1DWC_H_MITH1_1","ALPHA-THROMBIN (LARGE SUBUNIT)","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",5,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 226","None;PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);None;PBZ A 305 (-3.3A)","0.47A","1dwcH-1fiwA:34.8","1bcuH-1fizA:35.00"],["1DWC_H_MITH1_1","ALPHA-THROMBIN (LARGE SUBUNIT)","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",5,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 226","None;PBZ A 308 (-2.9A);PBZ A 308 (-3.2A);None;PBZ A 308 ( 3.7A)","0.41A","1dwcH-1fizA:34.3","1dwcH-1fiwA:31.51"],["1ETR_H_MITH1_1","EPSILON-THROMBIN","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","None;PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);None;PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.60A","1etrH-1fiwA:34.7","1dwcH-1fizA:35.00"],["1ETR_H_MITH1_1","EPSILON-THROMBIN","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","None;PBZ A 308 (-2.9A);PBZ A 308 (-3.2A);None;PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A)","0.54A","1etrH-1fizA:34.1","1etrH-1fiwA:34.12"],["1F5L_A_AMRA301_1","UROKINASE-TYPE PLASMINOGEN ACTIVATOR","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",4,"ASP A 189;SER A 195;GLY A 216;GLY A 226","PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.30A","1f5lA-1fiwA:36.6","1etrH-1fizA:35.46"],["1F5L_A_AMRA301_1","UROKINASE-TYPE PLASMINOGEN ACTIVATOR","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",4,"ASP A 189;SER A 195;GLY A 216;GLY A 226","PBZ A 308 (-2.9A);PBZ A 308 (-3.2A);PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A)","0.43A","1f5lA-1fizA:36.3","1f5lA-1fiwA:33.33"],["1TNL_A_TPAA900_1","TRYPSIN","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",4,"ASP A 189;SER A 195;GLY A 216;GLY A 226","PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.35A","1tnlA-1fiwA:16.2","1f5lA-1fizA:32.71"],["1TNL_A_TPAA900_1","TRYPSIN","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",4,"ASP A 189;SER A 195;GLY A 216;GLY A 226","PBZ A 308 (-2.9A);PBZ A 308 (-3.2A);PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A)","0.32A","1tnlA-1fizA:17.0","1tnlA-1fiwA:34.60"],["1X7P_B_SAMB302_0","RRNA METHYLTRANSFERASE","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",5,"THR A 190;GLY A 140;GLY A 142;ILE A 188;ALA A 158","PBZ A 305 (-3.9A);None;None;None;None","1.10A","1x7pA-1fiwA:undetectable;1x7pB-1fiwA:undetectable","1tnlA-1fizA:37.21"],["1X7P_B_SAMB302_0","RRNA METHYLTRANSFERASE","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",5,"THR A 190;GLY A 140;GLY A 142;ILE A 188;ALA A 158","PBZ A 308 (-3.4A);None;None;None;None","1.02A","1x7pA-1fizA:undetectable;1x7pB-1fizA:undetectable","1x7pA-1fiwA:23.03;1x7pB-1fiwA:23.03"],["2OTV_A_NCAA1301_0","CATIONIC TRYPSIN","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",4,"ASP A 189;SER A 195;GLY A 216;GLY A 226","PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.23A","2otvA-1fiwA:16.4","1x7pA-1fizA:19.47;1x7pB-1fizA:19.47"],["2OTV_A_NCAA1301_0","CATIONIC TRYPSIN","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",4,"ASP A 189;SER A 195;GLY A 216;GLY A 226","PBZ A 308 (-2.9A);PBZ A 308 (-3.2A);PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A)","0.36A","2otvA-1fizA:17.1","2otvA-1fiwA:34.60"],["2P16_A_GG2A298_1","COAGULATION FACTOR X (EC 3.4.21.6) (STUART FACTOR) (STUART-PROWER FACTOR)","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",6,"ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226;TYR A 228","PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);None;PBZ A 305 (-3.4A);PBZ A 305 (-3.3A);None","0.30A","2p16A-1fiwA:35.3","2otvA-1fizA:37.70"],["2P16_A_GG2A298_1","COAGULATION FACTOR X (EC 3.4.21.6) (STUART FACTOR) (STUART-PROWER FACTOR)","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",6,"ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226;TYR A 228","PBZ A 308 (-2.9A);PBZ A 308 (-3.2A);None;PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A);None","0.41A","2p16A-1fizA:34.1","2p16A-1fiwA:31.31"],["2VIN_A_505A1247_1","UROKINASE-TYPE PLASMINOGEN ACTIVATOR CHAIN B","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",4,"ASP A 189;SER A 195;GLY A 216;GLY A 226","PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.34A","2vinA-1fiwA:37.1","2p16A-1fizA:34.34"],["2VIN_A_505A1247_1","UROKINASE-TYPE PLASMINOGEN ACTIVATOR CHAIN B","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",4,"ASP A 189;SER A 195;GLY A 216;GLY A 226","PBZ A 308 (-2.9A);PBZ A 308 (-3.2A);PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A)","0.33A","2vinA-1fizA:14.1","2vinA-1fiwA:33.33"],["2W26_A_RIVA1001_1","ACTIVATED FACTOR XA HEAVY CHAIN","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",7,"ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 219;GLY A 226;TYR A 228","PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);None;PBZ A 305 (-3.4A);PBZ A 305 (-4.9A);PBZ A 305 (-3.3A);None","0.34A","2w26A-1fiwA:35.4","2vinA-1fizA:32.71"],["2W26_A_RIVA1001_1","ACTIVATED FACTOR XA HEAVY CHAIN","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",7,"ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 219;GLY A 226;TYR A 228","PBZ A 308 (-2.9A);PBZ A 308 (-3.2A);None;PBZ A 308 (-3.6A);None;PBZ A 308 ( 3.7A);None","0.50A","2w26A-1fizA:16.2","2w26A-1fiwA:31.31"],["3DCM_X_SAMX5452_0","UNCHARACTERIZED PROTEIN TM_1570","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",5,"THR A 190;GLY A 140;GLY A 142;ILE A 188;ALA A 158","PBZ A 308 (-3.4A);None;None;None;None","0.97A","3dcmX-1fizA:undetectable","2w26A-1fizA:34.34"],["3GY3_A_PNTA246_0","CATIONIC TRYPSIN","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",6,"ASP A 189;GLN A 192;SER A 195;TRP A 215;GLY A 216;GLY A 226","PBZ A 305 (-2.7A);PBZ A 305 (-3.2A);PBZ A 305 (-2.9A);None;PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.81A","3gy3A-1fiwA:16.4","3dcmX-1fizA:21.76"],["3GY3_A_PNTA246_0","CATIONIC TRYPSIN","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",6,"HIS A  57;ASP A 189;SER A 195;TRP A 215;GLY A 216;GLY A 226","None;PBZ A 305 (-2.7A);PBZ A 305 (-2.9A);None;PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.37A","3gy3A-1fiwA:16.4","3gy3A-1fiwA:34.60"],["3GY3_A_PNTA246_0","CATIONIC TRYPSIN","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",7,"HIS A  57;ASP A 189;GLN A 192;SER A 195;TRP A 215;GLY A 216;GLY A 226","None;PBZ A 308 (-2.9A);PBZ A 308 (-3.6A);PBZ A 308 (-3.2A);None;PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A)","0.56A","3gy3A-1fizA:16.9","3gy3A-1fiwA:34.60"],["3RXF_A_4APA9_1","CATIONIC TRYPSIN","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",4,"SER A 195;TRP A 215;GLY A 216;GLY A 226","PBZ A 305 (-2.9A);None;PBZ A 305 (-3.4A);PBZ A 305 (-3.3A)","0.28A","3rxfA-1fiwA:16.9","3gy3A-1fizA:37.70"],["3RXF_A_4APA9_1","CATIONIC TRYPSIN","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",4,"SER A 195;TRP A 215;GLY A 216;GLY A 226","PBZ A 308 (-3.2A);None;PBZ A 308 (-3.6A);PBZ A 308 ( 3.7A)","0.28A","3rxfA-1fizA:16.5","3rxfA-1fiwA:34.60"],["4FU8_A_ACTA302_0","UROKINASE-TYPE PLASMINOGEN ACTIVATOR","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",4,"HIS A  57;GLN A 192;GLY A 193;SER A 195","None;PBZ A 308 (-3.6A);None;PBZ A 308 (-3.2A)","0.87A","4fu8A-1fizA:36.4","3rxfA-1fizA:37.70"],["4LRH_B_FOLB301_1","FOLATE RECEPTOR ALPHA","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",3,"ASP A 102;TRP A  63;SER A 195","None;None;PBZ A 305 (-2.9A)","1.06A","4lrhB-1fiwA:undetectable","4fu8A-1fizA:32.10"],["4LRH_B_FOLB301_1","FOLATE RECEPTOR ALPHA","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",3,"ASP A 102;TRP A  63;SER A 195","None;None;PBZ A 308 (-3.2A)","1.07A","4lrhB-1fizA:undetectable","4lrhB-1fiwA:23.67"],["4RDX_A_HISA502_0","HISTIDINE--TRNA LIGASE","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",4,"THR A 190;GLY A 216;TYR A 228;GLY A 226","PBZ A 308 (-3.4A);PBZ A 308 (-3.6A);None;PBZ A 308 ( 3.7A)","0.91A","4rdxA-1fizA:undetectable","4lrhB-1fizA:23.08"],["6C2M_C_SUEC1203_0","NS3 PROTEASE","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",5,"HIS A  57;ASP A 102;GLY A 193;SER A 195;VAL A 217","None;None;None;PBZ A 305 (-2.9A);None","0.95A","6c2mC-1fiwA:9.7","4rdxA-1fizA:20.31"],["6C2M_C_SUEC1203_0","NS3 PROTEASE","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",5,"HIS A  57;ASP A 102;GLY A 193;SER A 195;VAL A 217","None;None;None;PBZ A 308 (-3.2A);None","0.88A","6c2mC-1fizA:9.5","6c2mC-1fiwA:16.10"],["6HU9_H_PCFH604_0","CYTOCHROME B-C1 COMPLEX SUBUNIT 8;CYTOCHROME C OXIDASE POLYPEPTIDE 5A, MITOCHONDRIAL","1fiw","BETA-ACROSIN HEAVY CHAIN","Ovis aries",4,"GLY A 216;GLY A 193;SER A 195;ALA A  55","PBZ A 305 (-3.4A);None;PBZ A 305 (-2.9A);None","0.76A","6hu9H-1fiwA:undetectable;6hu9e-1fiwA:undetectable","6c2mC-1fizA:16.47"],["6HU9_H_PCFH604_0","CYTOCHROME B-C1 COMPLEX SUBUNIT 8;CYTOCHROME C OXIDASE POLYPEPTIDE 5A, MITOCHONDRIAL","1fiz","BETA-ACROSIN HEAVY CHAIN","Sus scrofa",4,"GLY A 216;GLY A 193;SER A 195;ALA A  55","PBZ A 308 (-3.6A);None;PBZ A 308 (-3.2A);None","0.78A","6hu9H-1fizA:undetectable;6hu9e-1fizA:undetectable","6hu9H-1fiwA:14.79;6hu9e-1fiwA:18.21"]]